MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Retained Earnings 2011-2026 | ZOM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -300 M | -218 M | -171 M | -136 M | -119 M | - | -52.1 M | -32.3 M | -15.6 M | -158 K | -112 K | -78.7 K | -1.34 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.34 K | -300 M | -87.1 M |
Quarterly Retained Earnings Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -295 M | -289 M | -282 M | -218 M | -211 M | -204 M | - | -171 M | -149 M | -148 M | -143 M | -136 M | -134 M | -129 M | -123 M | -119 M | -116 M | -110 M | -105 M | -69 M | -69 M | -69 M | -69 M | -52.1 M | -52.1 M | -52.1 M | -52.1 M | -32.3 M | -32.3 M | -32.3 M | -32.3 M | -15.6 M | -15.6 M | -15.6 M | -15.6 M | -7.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.56 M | -295 M | -108 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.68 | 3.08 % | $ 1.37 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.06 | 4.1 % | $ 57.1 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.63 | 1.53 % | $ 2.05 B | Canada |
 |
Jupiter Wellness
JUPW
|
-183 M | - | - | $ 33.6 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.19 | -2.87 % | $ 128 M | Canada |
 |
Harrow Health
HROW
|
-157 M | $ 39.7 | 2.45 % | $ 1.46 B | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.45 | 0.7 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.35 | 0.86 % | $ 309 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 5.3 | -0.19 % | $ 342 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.51 | -1.31 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.03 | -0.74 % | $ 411 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 24.51 | -3.35 % | $ 1.13 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.01 | - | $ 4.36 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 18.04 | 0.11 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-958 M | $ 7.92 | -3.65 % | $ 693 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 7.21 | -0.55 % | $ 285 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 1.14 | -36.67 % | $ 1.41 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 6.75 | -2.74 % | $ 4.17 B | Canada |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 1.02 | -2.86 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.32 | 0.43 % | $ 313 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 14.59 | -1.08 % | $ 17.5 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.39 | 3.35 % | $ 86.3 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-403 M | $ 0.87 | 1.99 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-47.2 M | $ 0.61 | 1.65 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
-952 M | $ 2.19 | 0.46 % | $ 25.3 M | USA |